JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price target on AstraZeneca (LON:AZN) in a report published on Monday, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the subject of several other reports. Liberum Capital reaffirmed a hold rating and set a GBX 6,400 ($83.63) price objective on shares of AstraZeneca in a research report on Wednesday, August 28th. Barclays lifted their price objective on shares of AstraZeneca from GBX 7,800 ($101.92) to GBX 8,000 ($104.53) and gave the stock an overweight rating in a research report on Friday, September 6th. Deutsche Bank raised shares of AstraZeneca to a buy rating and lifted their price objective for the stock from GBX 7,200 ($94.08) to GBX 7,600 ($99.31) in a research report on Monday, September 2nd. UBS Group reaffirmed a sell rating on shares of AstraZeneca in a research report on Wednesday, August 21st. Finally, Credit Suisse Group set a GBX 7,300 ($95.39) price objective on shares of AstraZeneca and gave the stock a buy rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and an average target price of GBX 6,956.25 ($90.90).
Shares of AZN stock opened at GBX 6,904 ($90.21) on Monday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 7,583 ($99.09). The stock has a market capitalization of $90.57 billion and a PE ratio of 40.33. The firm has a 50 day moving average of GBX 7,124.24 and a two-hundred day moving average of GBX 6,384.29.
The business also recently declared a dividend, which was paid on Monday, September 9th. Investors of record on Thursday, August 8th were paid a dividend of GBX 71.90 ($0.94) per share. The ex-dividend date was Thursday, August 8th. This represents a yield of 1.07%. AstraZeneca’s dividend payout ratio is currently 1.28%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: What is the price-sales ratio?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.